Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine

N. S. Shahid, S. S. Hoque, T. Begum, M. C. Steinhoff, C. Thompson, G. R. Siber

Research output: Contribution to journalArticle

Abstract

Summary. Pneumococci are a leading cause of severe bacterial disease in infants and children world wide. A possible means of protecting infants in the first few months of life is immunisation of the mother during pregnancy. We prospectively assessed pneumococcal immunisation of pregnant women to determine the amount of pneumococcal antibody transmitted to the infants in serum and milk and the half-life of the passively acquired antibody. Healthy pregnant women in Dhaka, Bangladesh, were randomised to receive pneumococcal or meningococcal vaccine with routine prenatal tetanus immunisation at 30-34 weeks of gestation. Serum and breast milk specimens from the mothers and sera from infants were collected up to 22 weeks of age and assayed for specific serum IgG, IgG1, and IgG2 and for milk IgA antibodies to pneumococcal serotypes 6B and 19F. 55 mothers and 56 infants were followed from birth to five months. Women who received pneumococcal vaccine had geometric mean antibody increases of 2·6 and 3·4 to types 6B and 19F, respectively. The mean infant/maternal antibody ratios were 0·56 and 0·59 (range 0·11-1·46) for these serotypes. Infant cord antibody titres correlated with maternal titres. Infant/maternal IgG ratios correlated with the interval between immunisation and birth and were higher for specific IgG1 than for IgG2. Infants of pneumococcal vaccine recipients had geometric mean antibody concentrations of 6·8 and 7·5 μg/mL to serotypes 6B and 19F in cord blood; in cord blood and in all subsequent serum specimens the concentrations were 2-3 fold higher than in control infants. The median half-life of passive antibody was about 35 days; at five months of age 63-71% of infants of pneumococcal vaccine recipients had antibody concentrations greater than 0·15 μg/mL. Breast milk IgA antibodies for pneumococcal serotype 19F, but not for type 6B, were significantly higher in vaccine recipients up to five months after delivery. If maternal pneumococcal polysaccharide antibodies do not interfere with active immunisation of the infant with new glycoprotein conjugate pneumococcal vaccines, passive-active immunisation of infants can be a feasible strategy for developing regions.

Original languageEnglish (US)
Pages (from-to)1252-1257
Number of pages6
JournalThe Lancet
Volume346
Issue number8985
DOIs
StatePublished - Nov 11 1995

Fingerprint

Pneumococcal Vaccines
Human Milk
Immunization
Mothers
Antibodies
Serum
Immunoglobulin G
Fetal Blood
Immunoglobulin A
Half-Life
Pregnant Women
Milk
Vaccination
Parturition
Meningococcal Vaccines
Pregnancy
Conjugate Vaccines
Passive Immunization
Bangladesh
Tetanus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shahid, N. S., Hoque, S. S., Begum, T., Steinhoff, M. C., Thompson, C., & Siber, G. R. (1995). Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. The Lancet, 346(8985), 1252-1257. https://doi.org/10.1016/S0140-6736(95)91861-2

Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. / Shahid, N. S.; Hoque, S. S.; Begum, T.; Steinhoff, M. C.; Thompson, C.; Siber, G. R.

In: The Lancet, Vol. 346, No. 8985, 11.11.1995, p. 1252-1257.

Research output: Contribution to journalArticle

Shahid, NS, Hoque, SS, Begum, T, Steinhoff, MC, Thompson, C & Siber, GR 1995, 'Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine', The Lancet, vol. 346, no. 8985, pp. 1252-1257. https://doi.org/10.1016/S0140-6736(95)91861-2
Shahid NS, Hoque SS, Begum T, Steinhoff MC, Thompson C, Siber GR. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. The Lancet. 1995 Nov 11;346(8985):1252-1257. https://doi.org/10.1016/S0140-6736(95)91861-2
Shahid, N. S. ; Hoque, S. S. ; Begum, T. ; Steinhoff, M. C. ; Thompson, C. ; Siber, G. R. / Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. In: The Lancet. 1995 ; Vol. 346, No. 8985. pp. 1252-1257.
@article{377713a0e7574a02a64f122ae9d51f25,
title = "Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine",
abstract = "Summary. Pneumococci are a leading cause of severe bacterial disease in infants and children world wide. A possible means of protecting infants in the first few months of life is immunisation of the mother during pregnancy. We prospectively assessed pneumococcal immunisation of pregnant women to determine the amount of pneumococcal antibody transmitted to the infants in serum and milk and the half-life of the passively acquired antibody. Healthy pregnant women in Dhaka, Bangladesh, were randomised to receive pneumococcal or meningococcal vaccine with routine prenatal tetanus immunisation at 30-34 weeks of gestation. Serum and breast milk specimens from the mothers and sera from infants were collected up to 22 weeks of age and assayed for specific serum IgG, IgG1, and IgG2 and for milk IgA antibodies to pneumococcal serotypes 6B and 19F. 55 mothers and 56 infants were followed from birth to five months. Women who received pneumococcal vaccine had geometric mean antibody increases of 2·6 and 3·4 to types 6B and 19F, respectively. The mean infant/maternal antibody ratios were 0·56 and 0·59 (range 0·11-1·46) for these serotypes. Infant cord antibody titres correlated with maternal titres. Infant/maternal IgG ratios correlated with the interval between immunisation and birth and were higher for specific IgG1 than for IgG2. Infants of pneumococcal vaccine recipients had geometric mean antibody concentrations of 6·8 and 7·5 μg/mL to serotypes 6B and 19F in cord blood; in cord blood and in all subsequent serum specimens the concentrations were 2-3 fold higher than in control infants. The median half-life of passive antibody was about 35 days; at five months of age 63-71{\%} of infants of pneumococcal vaccine recipients had antibody concentrations greater than 0·15 μg/mL. Breast milk IgA antibodies for pneumococcal serotype 19F, but not for type 6B, were significantly higher in vaccine recipients up to five months after delivery. If maternal pneumococcal polysaccharide antibodies do not interfere with active immunisation of the infant with new glycoprotein conjugate pneumococcal vaccines, passive-active immunisation of infants can be a feasible strategy for developing regions.",
author = "Shahid, {N. S.} and Hoque, {S. S.} and T. Begum and Steinhoff, {M. C.} and C. Thompson and Siber, {G. R.}",
year = "1995",
month = "11",
day = "11",
doi = "10.1016/S0140-6736(95)91861-2",
language = "English (US)",
volume = "346",
pages = "1252--1257",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8985",

}

TY - JOUR

T1 - Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine

AU - Shahid, N. S.

AU - Hoque, S. S.

AU - Begum, T.

AU - Steinhoff, M. C.

AU - Thompson, C.

AU - Siber, G. R.

PY - 1995/11/11

Y1 - 1995/11/11

N2 - Summary. Pneumococci are a leading cause of severe bacterial disease in infants and children world wide. A possible means of protecting infants in the first few months of life is immunisation of the mother during pregnancy. We prospectively assessed pneumococcal immunisation of pregnant women to determine the amount of pneumococcal antibody transmitted to the infants in serum and milk and the half-life of the passively acquired antibody. Healthy pregnant women in Dhaka, Bangladesh, were randomised to receive pneumococcal or meningococcal vaccine with routine prenatal tetanus immunisation at 30-34 weeks of gestation. Serum and breast milk specimens from the mothers and sera from infants were collected up to 22 weeks of age and assayed for specific serum IgG, IgG1, and IgG2 and for milk IgA antibodies to pneumococcal serotypes 6B and 19F. 55 mothers and 56 infants were followed from birth to five months. Women who received pneumococcal vaccine had geometric mean antibody increases of 2·6 and 3·4 to types 6B and 19F, respectively. The mean infant/maternal antibody ratios were 0·56 and 0·59 (range 0·11-1·46) for these serotypes. Infant cord antibody titres correlated with maternal titres. Infant/maternal IgG ratios correlated with the interval between immunisation and birth and were higher for specific IgG1 than for IgG2. Infants of pneumococcal vaccine recipients had geometric mean antibody concentrations of 6·8 and 7·5 μg/mL to serotypes 6B and 19F in cord blood; in cord blood and in all subsequent serum specimens the concentrations were 2-3 fold higher than in control infants. The median half-life of passive antibody was about 35 days; at five months of age 63-71% of infants of pneumococcal vaccine recipients had antibody concentrations greater than 0·15 μg/mL. Breast milk IgA antibodies for pneumococcal serotype 19F, but not for type 6B, were significantly higher in vaccine recipients up to five months after delivery. If maternal pneumococcal polysaccharide antibodies do not interfere with active immunisation of the infant with new glycoprotein conjugate pneumococcal vaccines, passive-active immunisation of infants can be a feasible strategy for developing regions.

AB - Summary. Pneumococci are a leading cause of severe bacterial disease in infants and children world wide. A possible means of protecting infants in the first few months of life is immunisation of the mother during pregnancy. We prospectively assessed pneumococcal immunisation of pregnant women to determine the amount of pneumococcal antibody transmitted to the infants in serum and milk and the half-life of the passively acquired antibody. Healthy pregnant women in Dhaka, Bangladesh, were randomised to receive pneumococcal or meningococcal vaccine with routine prenatal tetanus immunisation at 30-34 weeks of gestation. Serum and breast milk specimens from the mothers and sera from infants were collected up to 22 weeks of age and assayed for specific serum IgG, IgG1, and IgG2 and for milk IgA antibodies to pneumococcal serotypes 6B and 19F. 55 mothers and 56 infants were followed from birth to five months. Women who received pneumococcal vaccine had geometric mean antibody increases of 2·6 and 3·4 to types 6B and 19F, respectively. The mean infant/maternal antibody ratios were 0·56 and 0·59 (range 0·11-1·46) for these serotypes. Infant cord antibody titres correlated with maternal titres. Infant/maternal IgG ratios correlated with the interval between immunisation and birth and were higher for specific IgG1 than for IgG2. Infants of pneumococcal vaccine recipients had geometric mean antibody concentrations of 6·8 and 7·5 μg/mL to serotypes 6B and 19F in cord blood; in cord blood and in all subsequent serum specimens the concentrations were 2-3 fold higher than in control infants. The median half-life of passive antibody was about 35 days; at five months of age 63-71% of infants of pneumococcal vaccine recipients had antibody concentrations greater than 0·15 μg/mL. Breast milk IgA antibodies for pneumococcal serotype 19F, but not for type 6B, were significantly higher in vaccine recipients up to five months after delivery. If maternal pneumococcal polysaccharide antibodies do not interfere with active immunisation of the infant with new glycoprotein conjugate pneumococcal vaccines, passive-active immunisation of infants can be a feasible strategy for developing regions.

UR - http://www.scopus.com/inward/record.url?scp=0028805501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028805501&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(95)91861-2

DO - 10.1016/S0140-6736(95)91861-2

M3 - Article

VL - 346

SP - 1252

EP - 1257

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8985

ER -